Kevin De Marchi
About Kevin De Marchi
Kevin De Marchi is a Manufacturing Associate Engineer at Bristol-Myers Squibb with over ten years of experience in Downstream Biologics Manufacturing.
Current Role at Bristol-Myers Squibb
Kevin De Marchi currently holds the position of Manufacturing Associate Engineer in the Downstream Technical Manufacturing Group at Bristol-Myers Squibb. He operates out of East Syracuse, NY. In this role, he leverages over ten years of experience in Downstream Biologics Manufacturing to contribute to the company's manufacturing processes.
Previous Positions at Bristol-Myers Squibb
Kevin De Marchi has held several positions at Bristol-Myers Squibb over the years. From 2017 to 2019, he served as an Associate Engineer in the Downstream Manufacturing Technology Group. Prior to that, he held the title of Senior Bioprocess Operator in the Biologics Manufacturing - Purification Department from 2014 to 2017. He began his tenure at the company as a Bioprocess Operator, a role he held from 2012 to 2014.
Employment at Aerotek
Before joining Bristol-Myers Squibb, Kevin De Marchi worked at Aerotek as a Bioprocess Associate in the Biologics Manufacturing - Purification Department. His employment at Aerotek lasted from 2011 to 2012 for a period of 8 months. This role marked the beginning of his career in biologics manufacturing.
Educational Background
Kevin De Marchi attended Allegheny College, where he studied Physics and earned a Bachelor of Science degree (BS). He completed his studies from 2004 to 2008. His academic background in physics has provided a solid foundation for his technical roles in bioprocessing and manufacturing.
Expertise and Responsibilities
Kevin De Marchi has authored GMP (Good Manufacturing Practice) documents and managed electronic change controls, including emergency, local, and global changes. He also acts as a Manufacturing Subject Matter Expert (SME) on capital projects and quality deviations. Additionally, he owns and manages Corrective Action/Preventative Action (CAPA) processes and has supported drug product investigations through a six-week rotation within the Bristol-Myers Squibb network.